Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Takeda Pharmaceutical ADR Rep 0.5 Ord Shs V.TAK


Primary Symbol: TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.


NYSE:TAK - Post by User

Takeda Pharmaceutical ADR Rep 0.5 Ord Shs > C2C Gold Shareholders Eric Sprott: 13.57% Sabre Gold 17.89%
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by wreckleson Oct 28, 2022 2:30pm
106 Views
Post# 35056513

RE:RE:C2C Gold Shareholders Eric Sprott: 13.57% Sabre Gold 17.89%

RE:RE:C2C Gold Shareholders Eric Sprott: 13.57% Sabre Gold 17.89%I wonder what C2C can sell to survive? 3 CEO's and 2 CFO's in one year is not good.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities